TLR7-based cancer immunotherapy decreases intratumoral myeloid-derived suppressor cells and blocks their immunosuppressive function.
about
NAB2 is a novel immune stimulator of MDA-5 that promotes a strong type I interferon response.Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy.Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines.Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer TherapyTurn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
P2860
TLR7-based cancer immunotherapy decreases intratumoral myeloid-derived suppressor cells and blocks their immunosuppressive function.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
TLR7-based cancer immunotherap ...... ir immunosuppressive function.
@en
type
label
TLR7-based cancer immunotherap ...... ir immunosuppressive function.
@en
prefLabel
TLR7-based cancer immunotherap ...... ir immunosuppressive function.
@en
P2093
P2860
P1433
P1476
TLR7-based cancer immunotherap ...... ir immunosuppressive function.
@en
P2093
Chiara Secondini
Christian Hotz
Curzio Rüegg
Inès Mottas
Lorenzo Spagnuolo
Marina Treinies
P2860
P304
P356
10.1080/2162402X.2016.1230578
P577
2016-09-09T00:00:00Z